|
市場調査レポート
商品コード
1172683
頭頸部がん治療薬の世界市場規模、シェア、産業動向分析レポート:治療タイプ別、投与経路別、流通チャネル別、地域別展望と予測、2022年~2028年Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type, By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
頭頸部がん治療薬の世界市場規模、シェア、産業動向分析レポート:治療タイプ別、投与経路別、流通チャネル別、地域別展望と予測、2022年~2028年 |
出版日: 2022年11月30日
発行: KBV Research
ページ情報: 英文 206 Pages
納期: 即納可能
|
世界の頭頸部がん治療薬市場規模は、2028年までに25億米ドルに達し、予測期間中にCAGR12.3%の市場成長率で上昇すると予測されています。
外科的介入、放射線治療、化学療法、標的療法、免疫療法が主ながん治療法です。治療計画には、外科的処置または放射線療法のみ、あるいはその2つの混合が含まれる場合があります。特定の頭頸部がんの挙動は、その発生場所(原発部位)に依存します。
例えば、声帯に発生した腫瘍と、声帯から1センチほどしか離れていない舌の裏側に発生した腫瘍では、その挙動が全く異なります。鼻、口、喉の内部を覆っている細胞から発生する扁平上皮がんは、頭頸部のがんの中で最も多く見られるものです。
COVID-19影響度分析
COVID-19の流行は、さまざまなタイプの頭頸部がん患者の治療に大きな影響を与え、高齢の患者、主に外科手術を受ける患者、合併症の少ない患者に大きな影響を及ぼしています。これらの患者さんは、診断の見落としや遅れにより、より悪い腫瘍学的転帰をたどる可能性があります。COVID-19の流行により、いくつかのがん検査が延期または再スケジュールされ、相当数の人々が必要な医療処置を受けられないままになっています。このようながん検診プログラムの中断は、患者、医療従事者、医療制度に大きな影響を与える可能性があります。
市場の成長要因
免疫療法に対する需要の高まり
免疫療法は、頭頸部がん、リンパ腫、メラノーマ、非小細胞肺がんなど、がんに対する革新的な治療法です。腫瘍の中には、化学療法などの従来の治療法によく反応するものがあります。また、がんに対する身体の自然な防御力を高めるために、従来のがん治療法に免疫療法を併用する場合もあります。免疫システムは、その通常の機能の一部として、異常な細胞を発見し排除することで、いくつかの悪性腫瘍の形成を防止または抑制しています。例えば、免疫細胞は、腫瘍の中やその周囲に見られることがあります。
市場成長の原動力となる患者数の増加
頭頸部がんは、その部位によって分類されます。これらの部位には、口腔、咽頭、喉頭、副鼻腔、鼻腔、唾液腺が含まれます。頭頸部がんの主な原因として、アルコールとタバコの摂取量の増加が挙げられます。頭頸部がんの75%はアルコールとタバコの摂取が原因と推定されています。がんは死亡原因のトップとなり、死亡者数1,000万人以上、すなわち死亡者数の6人に1人を占めます。
市場抑制要因
化学療法に伴う副作用
頭頸部がんは、放射線療法と化学療法を組み合わせた治療が行われることが多いです。その副作用として、脱毛、言語障害、地声の喪失などがあります。また、がんの手術を受けると、食事がしづらくなります。脱毛は化学療法の副作用として頻繁に起こりますが、すべての人に起こるわけではありません。個人は、薬の副作用である可能性が高いかどうか、担当の医師に尋ねることができます。
治療法の種類
頭頸部がん治療薬市場は、治療法の種類に基づいて、化学療法、免疫療法、標的療法に区分されます。2021年の頭頸部治療薬市場では、免疫療法分野が最も高い収益シェアを獲得しています。それは、免疫療法ががんを治療するために免疫システムを利用するからです。DNAを修復する能力に欠ける細胞を標的とする抗PD1免疫療法であるPembrolizumabは、このカテゴリーに分類される可能性があります。
投与経路の展望
頭頸部がん治療薬市場は、投与経路の違いにより、注射剤と経口剤に分けられます。経口セグメントは、2021年の頭頸部がん治療薬市場において、かなりの収益シェアを獲得しています。頭頸部がん患者の治療に使用される経口医薬品の数が増加しているためです。試験の成功裏の終了とその後の発売がセグメントの成長を刺激すると予想されます。また、がん患者には経口化学療法が実施されています。
流通経路の展望
流通経路別に見ると、頭頸部がん治療薬市場は、小売・専門薬局、病院内薬局、オンライン薬局に分類されます。小売・専門薬局は、2021年の頭頸部がん治療薬市場において最も高いセグメント収益シェアを示しています。それは、専門薬局が免疫療法薬など、従来の薬局では入手できない薬を提供しているからです。専門薬局を通じてこれらの薬剤を提供することで、その適切かつ安全な配達が保証されます。
地域別の展望
地域別では、頭頸部がん治療薬市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2021年の頭頸部がん治療薬市場において最大の収益シェアを登録しました。これは、ヘルスケア分野の拡大に対する政府の援助、魅力的な診療報酬規則、病気に対する高い認識、質の高い医療施設への容易なアクセスなどが、同地域の市場拡大に寄与している要因として挙げられます。
List of Figures
The Global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 12.3% CAGR during the forecast period.
The majority of malignancies that are jointly referred to as head and neck cancers begin in the squamous cells that cover the mucosal surfaces of the head and neck. These tumors are known as head and neck squamous cell carcinomas. Head and neck malignancies can also begin in the salivary glands, muscles, sinuses, or nerves in the head and neck, however, squamous cell carcinomas are noticeably more common.
Numerous malignancies of the head and neck are curable, especially if detected early. Although eradicating cancer is the major objective of therapy, maintaining the function of the surrounding nerves, organs, and tissues is equally crucial. When planning therapy, physicians examine how treatment may influence a patient's quality of life, including how the patient feels, looks, speaks, eats, and breathes.
Surgical intervention, radiation treatment, chemotherapy, targeted therapy, and immunotherapy are the primary cancer treatments. Surgical procedures or radiation therapy alone, or a mix of the two, may be included in the treatment plan. The behavior of a specific head-neck cancer relies on its origin place (the primary site).
For instance, tumors that develop in the vocal cords behave quite differently from those that begin in the backside of the tongue, which is just an inch or less away from the vocal cords. Squamous cell carcinoma, which comes from the cells that cover the interior of the nose, mouth, and throat, is the most prevalent kind of cancer of the head and neck.
COVID-19 Impact Analysis
The COVID-19 pandemic has significantly impacted the care of different types of Head and neck cancer patients, having a greater impact on older patients, individuals operated primarily surgically, and those with fewer comorbidities. These individuals may experience poorer oncological outcomes due to missing or delayed diagnosis. Due to the COVID-19 pandemic, several cancer tests have been delayed or rescheduled, leaving a substantial number of people without access to required healthcare treatments. This interruption to cancer screening programs may have substantial consequences for patients, medical professionals, and health systems.
Market Growth Factors
Increasing Demand For Immunotherapy Treatment
Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to conventional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body's natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, for instance, are occasionally seen in and surrounding tumors.
Increasing Patient Population To Drive Market Growth
Head and neck cancers are classified according to their location. These regions include the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, as well as the salivary glands. An increase in alcohol and cigarette intake is a key cause of head and neck cancer. An estimated 75% of head and neck cancers are caused by alcohol and cigarette intake. Cancer will be the top cause of mortality, accounting for over 10 million fatalities, or one in six deaths.
Market Restraining Factors
Associated Side Effects Of Chemotherapy
Cancer of the head and neck are frequently treated with a mix of radiation and chemotherapy treatment. The adverse effects include hair loss, speech impairment, and loss of natural voice. In addition, after undergoing cancer surgery, people have difficulty eating. Although hair loss is a frequent side effect of chemotherapy, it does not affect everyone. Individuals can ask their care provider whether it is likely a medication side effect.
Therapy Type Outlook
Based on the Therapy Type, the Head and Neck Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and Targeted Therapy. The immunotherapy segment acquired the highest revenue share in the head and neck therapeutics market in 2021. It is because immunotherapy make use of the immune system to treat cancer. Pembrolizumab, an anti-PD1 immunotherapy that targets cells with a deficiency in their capacity to repair DNA, may fall under this category.
Route of Administration Outlook
On the basis of the Route of Administration, the Head and Neck Cancer Therapeutics Market is divided into Injectable and Oral. The oral segment garnered a substantial revenue share in the head and neck cancer therapeutics market in 2021. Due to the rising number of oral medicinal medicines used to treat patients with Head and neck cancer. It is anticipated that the successful conclusion of the study and subsequent launch will stimulate segment growth. Patients with cancer are also administered oral chemotherapy.
Distribution Channel Outlook
By Distribution Channel, the Head and Neck Cancer Therapeutics Market is classified into Retail and Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The retail and specialty pharmacies witnessed the highest segment revenue share in the head and neck cancer therapeutics market in 2021. It is because specialty pharmacies offer medications unavailable in conventional pharmacies, such as immunotherapy drugs. Providing these drugs through a specialty pharmacy guarantees their appropriate and secure delivery.
Regional Outlook
Region-wise, the Head and Neck Cancer Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment registered the largest revenue share in the head and neck cancer therapeutics market in 2021. It is due to the government assistance for the expansion of the healthcare sector, attractive reimbursement rules, a high level of illness awareness, and easy access to high-quality healthcare facilities are among the factors that have contributed to the expansion of the regional market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
Strategies Deployed in Head And Neck Cancer Therapeutics Market
Aug-2022: Sanofi came into collaboration with Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures, and commercializes medicines for cancer treatment. Through this collaboration, the company aims to accelerate the development and future commercialization of oncology medicines as well as strengthen its presence in oncology in China.
Jul-2022: AstraZeneca completed the acquisition of TeneoTwo, comprising obtaining the rights to TNB-486, a BiTE currently in Phase I for R/R B-cell non-Hodgkin lymphoma. With this acquisition, the company broadened its hematology portfolio.
Feb-2022: Sanofi took over Amunix Pharmaceuticals, an immuno-oncology company. Through this acquisition, the company gets access to Amunix XPAC technology, Pro-XTEN, and XPAT which complement the company's existing R&D platform that further helps in accelerating and expanding innovative oncology medicines. Through this acquisition, Sanofi enhances its immuno-oncology portfolio by adding Amunix's promising pipeline.
Mar-2021: Takeda Pharmaceutical Company Limited came into an agreement to acquire Maverick Therapeutics, Inc., a private biopharmaceutical company developing conditionally active bispecific T-cell targeted immunotherapies. With this acquisition, the company would expand its Immuno-Oncology Portfolio with Maverick's Conditionally Active Bispecific T-cell Engagers COBRA Platform, which is designed to Target Solid Tumors.
Nov-2020: Merck (MSD) came into an agreement to acquire all outstanding shares of VelosBio, a portfolio company of Pappas Capital. Through this acquisition, Merck will strengthen its oncology pipeline with the addition of VLS-101, VelosBio's lead investigational candidate.
Sep-2020: Takeda Pharmaceutical opened a new R&D headquarters in Boston, Massachusetts. The new facility focuses on enhancing the development and end-to-end research capabilities of the company to develop cell therapies with the potential to expand into other therapeutic areas.
Aug-2020: Teva Pharmaceutical Industries joined hands with Alvotech, a combined biopharmaceutical company. Through this collaboration, Alvotech would allow Teva to access its technical expertise in working with the FDA to bring products to the U.S. market while enlarging its growing biosimilar offering and utilizing its unique cross-functional expertise throughout both generic and specialty medicines.
Oct-2018: AstraZeneca and MedImmune, the research and development division expanded its existing collaboration with Innate Pharma (Innate), a biotech company, that focuses on clinical-stage oncology. Through this collaboration, both companies are looking forward to innovate new medicines which accelerate their oncology portfolio.
Feb-2018: Bristol-Myers Squibb teamed up with Nektar Therapeutics, the global biopharmaceutical company. Through this collaboration, the companies would jointly create and market NKTR-214 in integration with Bristol-Myers Squibb's Opdivo and Opdivo plus Yervoy in more than 20 presentations across 9 tumor types, along with potential mixtures with other anti-cancer representatives from either of the individual businesses and/or third parties.
Market Segments covered in the Report:
By Therapy Type
By Route of Administration
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research